Rekombinanter ITGA5 (Volociximab Biosimilar) Antikörper

Produktnummer ABIN5668271

Dieser Kaninchen Chimeric Antikörper detektiert spezifisch ITGA5 (Volociximab Biosimilar) in FACS, BR, ELISA, IF, IHC (p) und IHC (fro). Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für Rekombinanter ITGA5 (Volociximab Biosimilar) Antikörper (ABIN5668271)

Target: ITGA5 (Volociximab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Unkonjugiert

Applikation: Flow Cytometry (FACS), Blocking Reagent (BR), ELISA, Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Klon: M200

Produktdetails

Verwendungszweck: Anti-alpha 5 beta 1 Integrin [M200 (Volociximab)], Rabbit IgG, kappa

Spezifität:

This antibody is specific for human α5β1 integrin. Cross-reactivity studies revealed no binding to other human integrins such as α3β1, αvβ3, or αvβ5. It does, however, bind to α5β1 in the vasculature of cynomolgus monkeys, but not in mice. α5β1 is part of the integrin superfamily-glycoprotein transmembrane receptors that interact with ligands such as fibronectin, vitronectin, laminins, and collagens. This receptor plays a key role in processes including inflammation, cell proliferation, angiogenesis, and tumor metastasis.

Application Notes original Clone: This antibody binds human α5β1 integrin with high affinity (Kd = 0.367 nM, EC₅₀ = 0.2 nM, IC₅₀ = 2.3 nM) and, in chimeric mouse-human IgG4 form, demonstrated potent anti angiogenic and anti tumor effects in preclinical models (laser induced CNV in cynomolgus monkeys, VX2 carcinoma in rabbits) before progressing into Phase II trials in platinum resistant ovarian cancer (Ramakrishnan et al., 2006, PMID: 17024968, Bhaskar et al., 2007, PMID: 17786386). Exclusive binding to α5β1 (no cross reactivity with α3β1, αvβ3, αvβ5) was confirmed by ELISA. Immunohistochemistry (IHC-F) demonstrated binding to cynomolgus vasculature but not to mouse tissue. Studies with recombinant integrin subunits revealed that binding depends specifically on the human α5 chain, while the β1 chain can be of either human or mouse origin, indicating strict specificity for the α5β1 heterodimer (Bukowski et al., 2009, DOI: 10.1007/978-1-59745-332-5). In clinical testing, weekly 15 mg/kg IV dosing achieved trough serum levels >150 μg/mL, with 2-3x accumulation by Day 50, detectable antibody in ascites, reduction in circulating endothelial progenitor cells, and a favorable safety profile. The use of this antibody in IHC-P was demostrated (Bell McGuinn et al., 2011, PMID: 21276608). Clone F200, a Fab derivative of M200, is available upon request.

Produktmerkmale: NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.

Aufreinigung: Protein A affinity purified

Reinheit: > 98 % as determined by SDS-PAGE

Endotoxin-Niveau: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: Heterodimeric alpha5beta1Fc fusion protein

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Kommentare:

OriginalSpeciesName: Human

OriginalFormat: IgG4

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Antigendetails

Target: ITGA5 (Volociximab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: Fibronectin receptor, CD49 antigen-like family member E, Integrin alpha-F, VLA-5, CD49e.

UniProt: P08648